PREVENT Cancer Preclinical Drug Development Program (cGMP)

IDIQ

Description

Provide the production of vaccines and biologicals for cancer prevention. The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. Research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.

Overview

Ceiling

$49,995,000

Primary Sponsoring Agency

National Cancer Institute (NCI) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Primary PSC

R499 - Support- Professional: Other

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and Biologicals for Cancer Prevention (N01CN87006-18)

Successor

Region 2 Vegetation Management Services IDIQ

PREVENT Cancer Preclinical Drug Development Program (cGMP) awarded by National Cancer Institute (NCI) in August 2019 accepts orders through January 2024. The IDIQ has a reported ceiling of $49,995,000, and as of today, $4,449,286 has been obligated through the vehicle with a total reported backlog of $1,046,235. The IDIQ was awarded full & open and has a primary NAICS code of 541714.

Award Hierarchy

Vehicle

PREVENT Cancer Preclinical Drug Development Program (cGMP)

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

8/14/19

Start Date

1/24/24

Ordering Period End Date

100% Complete

Task Order Obligations and Backlog

$4.4M

Total Obligated

$4.4M

Current Award

$5.5M

Potential Award

81% Funded

$0.0

Funded Backlog

$1.0M

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for PREVENT Cancer Preclinical Drug Development Program (cGMP)

Vehicle Award Share

Federal Award Analysis